Head to Head Contrast: Osiris Therapeutics (OTCMKTS:OSIR) versus Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN) and Osiris Therapeutics (OTCMKTS:OSIR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Valuation and Earnings

This table compares Dyne Therapeutics and Osiris Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.33)	-8.02
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Dyne Therapeutics and Osiris Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	2	10	2	2.87
Osiris Therapeutics	0	0	0	0	0.00

Dyne Therapeutics currently has a consensus price target of $34.42, indicating a potential upside of 28.85%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Dyne Therapeutics is more favorable than Osiris Therapeutics.

Institutional & Insider Ownership

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 43.4% of Osiris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and Osiris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Osiris Therapeutics	N/A	N/A	N/A

Summary

Dyne Therapeutics beats Osiris Therapeutics on 5 of the 8 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.